Swizzer...Sorry to disappoint you; but, do not expect anything to come out of the Second International Congress on Neuropathic Pain, being held in Berlin, Germany on June 7 to 10, 2007. Avanir has through the years attended and presented at many of these and have never come out of them with anything. They are just going to do their presentation of the Phase III data on the efficacy, safety and improvements in patient-centered outcomes in patients with diabetic peripheral neuropathic (DPN) pain treated with the investigational drug Zenvia™ (dextromethorphan / quinidine) and, hope to gain acceptance of it throughout Europe and other countries later on. That, however, is down the road.
As for financing??? I know in their May 9, 2007 PR they stated, "We are working aggressively to solidify our financial position to fund our clinical development programs, which include cost cutting and restructuring measures announced in March. We are actively evaluating several strategic options simultaneously, with a goal to raise sufficient funds to finance operating expenses for the next two years, while minimizing shareholder dilution." Other than that, they have given no other indication(s) as to how they are going about arranging for financing. Hopefully, we'll know in the next couple of months.
G' day Mate,
Aussie
News 
Market Data 
Discover 
AI
